UCB’s $1.15 Billion Bet on Neurona Signals Major Push into Pluripotent Stem Cell–Derived Cell Therapy

In one of the largest regenerative medicine deals of 2026 to date, UCB announced plans to acquire Neurona Therapeutics in a transaction valued at an astounding price tag: up to $1.15 billion. The deal includes $650M upfront, with an additional $500M tied to future milestones.  The acquisition represents a pivotal strategic shift for UCB, marking its entry into the rapidly advancing field of cell therapy, specifically therapies derived from pluripotent stem cells. While UCB has built a strong legacy in epilepsy over the past 30 years, this move signals a transition beyond traditional pharmacological approaches toward regenerative, potentially disease-modifying interventions.

Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC) 

SEATTLE, WA and CAMBRIDGE, UK, May 1, 2026 — Pluristyx, a leading provider of clinical-grade iPSC solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, announced a distribution agreement to support streamlined and efficient R&D and manufacturing of differentiated cells and tissues from iPSC. This collaboration will provide researchers, product manufacturers, and therapeutic developers with a streamlined, high-performance workflow, pre-qualified to deliver reliable differentiation of iPSCs into product cells and tissues.

Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges

Toulouse, 2026 April 16^th  – Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field.

South Korean-based “iPS Bio” Establishes Japanese Subsidiary, Deepening Ties to Japan’s iPSC Ecosystem

A South Korea–based regenerative medicine company, iPS Bio, Inc., is accelerating its international footprint with the establishment of a new Japanese subsidiary in Yokohama, Kanagawa Prefecture. The move reflects a broader trend of cross-border collaboration in the induced pluripotent stem cell (iPSC) sector, particularly between leading innovation hubs in East Asia.

RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China

FREDERICK, MD., April 8, 2026 — RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, announced an exclusive distributor partnership with MineBio Life Sciences, a trusted partner to China’s biopharmaceutical and advanced therapy community. MineBio will distribute RoosterBio’s full platform of research-grade and CliniControl^TM cGMP-grade MSC and exosome bioprocessing media throughout China. Critically, MineBio has already secured import approval for RoosterBio’s research use only and cGMP CliniControl^TM MSC and exosome bioprocessing media platform, enabling orders to be fulfilled without delay.

Cartherics and Catalent Expand Commercial License Agreement

MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., have announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant iPSC line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. 

iPSC Therapies Make History: Japan Authorizes World’s First Two iPSC-based Cell Therapies

Recently, the world witnessed the approval of the world’s first two iPSC-derived medicines, as Japan’s health ministry panel authorized their commercialization on February 19, 2026. The approved therapies are ReHeart, developed by Cuorips Inc., a regenerative medicine company spun out of research at Osaka University, and Amchepry, developed by Sumitomo Pharma Co., Ltd. in collaboration with Racthera Inc.

L2 Bio, LLC Launches C-ROW Site Beta: A Breakthrough Research Project in Costa Rica Targeting Osteoarthritis

ESCAZU, COSTA RICA, June 1,  2026 — L2 Bio, LLC has formally announced the launch of the C-ROW Site Beta (C-ROW), an innovative, participant-funded research project based in Costa Rica welcoming the safety and convenience of utilizing local participation of your USA or Canadian based doctor. The study centers on the use of enhanced autologous adipose-derived stem cells (ADSCs) to address the debilitating progression of osteoarthritis.

MSCs as “Therapeutic Workhouses” in the Era of Regenerative Medicine

MSCs are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum,  a layer of connective tissue that envelops the bones. They are also known as: Mesenchymal Stem Cells, Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells.

Top iPSC Providers Transforming Preclinical Safety for Big Pharma

The pharmaceutical industry continues to grapple with preclinical and clinical safety issues, with toxicity remaining a leading cause of drug failure. Cardiovascular toxicity, in particular, stands out, accounting for approximately 40% of all drug withdrawals due to safety concerns. To mitigate these risks, human iPSC-derived cardiomyocytes (iPSC-CMs) have emerged as a critical tool for evaluating cardiac safety. Traditionally, most studies have relied on iPSC-CMs from one or two healthy donors, limiting the representation of broader population variability in the drug response.

Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering

In recent months, a striking trend has emerged. Major pharma companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body has moved from speculative science to strategic priority. Recently, the field has transformed with AstraZeneca, AbbVie, Gilead’s Kite Pharma, and Bristol Myers Squibb all making acquisitions designed to accelerate their capabilities in in vivo cell therapy. Each deal highlights the growing importance of technologies that can directly engineer immune cells without removing them from the body.  

The Remarkable Rise of iPSC-derived MSC Therapeutics: iMSCs

The rise of iPSC-derived mesenchymal stem cells (iMSCs) represents a significant evolution in regenerative medicine. iMSCs are generated by reprogramming adult somatic cells, typically fibroblasts, into induced pluripotent stem cells (iPSCs), which are then differentiated into mesenchymal stem cells (MSCs). This breakthrough technology offers several advantages over traditional MSC therapies, which are often derived from limited, patient-specific sources such as bone marrow or adipose tissue.

[FLASH SALE] Global Regenerative Medicine Industry Database, 2026 - Featuring 1,920+ Companies

Regenerative medicine (RM) companies are continuing to multiply rapidly. There are now an astonishing 1,920+ companies developing RM products to advance human health. This database is designed to help you identify all known market participants in this fast-growing field, including competitors, collaborators, or acquisition targets. RM companies include those advancing stem cell therapies, cell and gene therapies, tissue engineering and biomaterials, direct cell reprogramming, exosome therapeutics, cellular scaffolds and matrices, 3D bioprinting, and more. 

For a limited time, you can claim it for an unusual 50% off.

Interested to learn about other market segments, such as MSCs, iPSCs, CAR-T cells, exosomes, cord blood, or the cell therapy industry at large? 

To view all available products, explore the BIOINFORMANT SHOP. 

*Interested to advertise in this newsletter? Contact Info@BioInformant.com